Klozapin yaklaşık 40 yıldır şizofreni tedavisinde kullanılmaktadır ve kayda değer yan etkileri bulunmasına rağmen, tedaviye dirençli şizofrenide halen altın standarttır. Klozapin tedavisi sırasında sık karşılaşılan ve hastaların yaşam kalitesini önemli düzeyde etkileyebilen bir yan etki de siyaloredir. Klozapinin belirgin antikolinerjik yan etkilerine karşın, halen hangi mekanizmayla siyaloreye neden olduğu net biçimde bilinmemektedir. Sık karşılaşılmasına ve yaşam kalitesini belirgin biçimde etkileyebilmesine rağmen, siyalorenin tedavisinde halen mevcut seçeneklerin başarı oranı kısıtlıdır. Bu yazıda, klozapine bağlı gelişen siyalorenin patofizyolojisi ve tedavi seçenekleri güncel bilgiler ışığında gözden geçirilmiştir.
Clozapine has been used for approximately 40 years and it is still the gold standard for treatment resistant schizophrenia even though it may cause considerable side effects. One of the common side effects during the treatment with clozapine is sialorrhea. Although clozapine has anticholinergic side effects, pathogenesis of sialorrhea is still unclear. Despite sialorrhea is quite common and might influence quality of life, treatment choices and their efficacy for this side effect is limited. Thus, in this article, pathophysiology and treatment of clozapin induced sialorrhea is reviewed.
1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozaril Collaborative Group: Clozapine for treatment resistant schizophrenia: A double-blind comparison with chlorpromazine. Arch Gen Psych 1988: 45;789-796.
2. Wagstaff A, Perry C. Clozapine: in prevention of suicide in patients with schizophrenia or schizo-affective disorder. CNS Drugs 2003: 17;273–280.
3. Van Kammen DP, Marder SR. Serotonin–dopamine antagonists (atypical or second generation antipsychotics): In Sadock BJ, Sadock VA (editors). Kaplan & Sadock’s comprehensive textbook of psychiatry, vol. 2. Philadelphia: Lippincot Williams & Wilkins, 2005, 2914–2938.
4. Rogers D, Shramko J. Therapeutic options in the treatment of clozapine-induced sialorrhoea. Pharmacotherapy 2000: 20;1092– 1095.
5. Cree A, Mir S, Fahy T. A review of the treatment options for clozapine-induced hypersalivation. Psychiatr Bull 2001: 25;114– 116.
6. Ben-Areyh H, Jungeman T, Szargel R, Klein E, Laufer D. Salivary flow-rate and composition in schizophrenic patients on clozapine: subjective reports and laboratory data. Biol Psychiatry 1996: 39;946–949.
7. Gaftanyuk O, Trestman RL. Scolpolamine patch for clozapineinduced sialorrhea. Psychiatr Serv 2004: 55;318.
8. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross over study. Int Clin Psychopharmacol 2006: 21;99–103.
9. Safferman A, Liberman J, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991: 17;247–261.
10. Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998: 24;381–390.
11. Hinkes R, Quesada TV, Currier MB, Gonzalez-Blanco M. Aspiration pneumonia secondary to clozapine-induced sialorrhea. Br J Psychiatry 1996: 169;390–391.
12. Boyce HW, Bakheet MR. Sialorrhea: a review of a vexing, often unrecognized sign of oropharyngeal and esophageal disease. J Clin Gastroenterol 2005: 39;89–97.
13. Reinstein MJ, Sirotovskaya LA, Chasanov MA, Jones LE. Comparative efficacy and tolerability of benztropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Investig 1999: 17;97–102.
14. Freudenreich O, Beebe M, Goff DC. Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series. J Clin Psychopharmacol 2004: 24;98–100.
15. Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, Xia J. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev 2008: 3;CD005579.
16. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992: 63;51- 70.
17. Vasile JS, Steingard S. Clozapine and the development of salivary gland swelling: a case study. J Clin Psychiatry 1995: 56;511–513.
18. Brodkin ES, Pelton GH, Price LH. Treatment of clozapine induced parotid gland swelling. Am J Psychiatry 1996: 153;445.
19. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: a doubleblind, dose-ranging study. Arch Pediatr Adolesc Med 2000: 154;1214– 1218.
20. Grabowski J. Clonidine treatment of clozapine-induced hypersalivation. J Clin Psychopharmacol 1992: 12;69–70.
21. Carlson GW. The salivary glands. Embryology, anatomy, and surgical applications. Surg Clin North Am 2000: 80;261–273.
22. Corrigan FM, MacDonald S. Clozapine-induced hypersalivation and the alpha 2 adrenoceptor. Br J Psychiatry 1995: 167;412.
23. Zorn SH, Jones SB, Ward KM, Liston DR. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 1994: 269;R1–R2.
24. Chatelut E, Rispail Y, Berlan M, Montastruc JL. Yohimbine increases human salivary secretion. Br J Clin Pharmacol 1989: 28;366–368.
25. Mandel ID, Zengo A, Katz R, Wotman S. Effect of adrenergic agents on salivary composition. J Dent Res 1975: 54;27–33.
26. Rabinowitz T, Frankenburg F, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 1996: 40;1132–1134.
27. Ogura C, Kishimoto A,Mizukawa R. Comparative study of the effects of 9 antidepressants on several physiological parameters in healthy volunteers. Neuropsychobiology 1987: 17;139–144.
28. Szabadi E. Clozapine-induced hypersalivation and the alpha-2 adrenoceptor. Br J Psychiatry 1996: 169;380–381.
29. Ichikawa J, Dai J, O’Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002: 26;325–339.
30. Michal P, Lysikova M, El-Fakahany EE, Tucek S. Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors. Eur J Pharmacol 1999: 376;119–125.
31. Bourgeois JA, Drexler KG, Hall MJ. Hypersalivation and clozapine. Hosp Community Psychiatry 1991: 42;1174.
32. Pitcher JL. Safety and effectiveness of the modified Sengstaken– Blakemore tube: a prospective study. Gastroenterology 1971: 61;291–298.
33. Terry R, Frances RF, Franca C, Judith K. The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 1996: 40;1132– 1134.
34. Pearlman C. Clozapine, nocturnal sialorrhea, and choking. J Clin Psychopharmacol 1994: 14;283.
35. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 1992: 160;12–16.
36. Davydov L, Botts SR. Clozapine-induced hypersalivation. Ann Pharmacother, 2000: 34:662–665
37. Nemeroff CB, Putnam JS. α2-Adrenergic receptor agonists: clonidine and guanfacine: In Sadock BJ, Sadock VA (editors). Kaplan & Sadock’s comprehensive textbook of psychiatry, vol. 2. Philadelphia: Lippincot Williams & Wilkins, 2005, 2718–2722.
38. Praharaj SK, Verma P, Roy D, Singh A. Is clonidine useful for treatment of clozapine-induced sialorrhea? J Psychopharmacol 2005: 19;426–428.
39. Webber MA, Szwast SJ, Steadman TM, Frazer A, Malloy FW, Lightfoot JD, Shekhar A. Guanfacine treatment of clozapine induced sialorrhea. J Clin Psychopharmacol 2004: 24;675–676.
40. Fritze J, Elliger T. Pirenzepine for clozapine-induced hypersalivation. Lancet 1995: 346;1034.
41. Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol 2001: 21;608–611.
42. Schneider B, Weigmann H, Hiemke C, Weber B, Fritze J. Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 2004: 37;43–45.
43. Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A. Trihexyphenidyl treatment of clozapine-induced hypersalivation. Int Clin Psychopharmacol 1997:12;213–215.
44. Richardson C, Kelly DL, Conley RR. Biperiden for excessive sweating from clozapine. Am J Psychiatry 2001: 158;1329–1330.
45. Lin H. A double blind control study of propantheline and placebo in the treatment of clozapine-induced hypersalivation. Chinese Journal of Nervous Mental Disorders 1999: 25;316–317.
46. Gong GQ, Yuan LX, Tan D, Li HJ, Zhao LX, Hu CF, Yang XT, Li XW, Lu CJ, Chen HM, Liu G, Yi WZ, Zhou SC, Zheng LB. Effectiveness of diphenhydramine, propantheline, hismanal and placebo in the treatment of clozapine-induced hypersalivation: A double blind control study. Clinical Journal of Psychiatry 1998: 31;138.
47. McKane JP, Hall C, Akram G. Hyoscine patches in clozapine induced hypersalivation. Psychiatr Bull 2001: 25;277.
48. Thorburn JR, James MF, Feldman C, Moyes DG, Du Toit PS. Comparison of the effects of atropine and glycopyrrolate on pulmonary mechanics in patients undergoing fibreoptic bronchoscopy. Anesth Analg 1986: 65;1285–1289.
49. Tessier P, Antonello C. Clozapine and sialorrhea: update. J Psychiatry Neurosci 2001: 26;253.
50. Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord 2002: 17;1318–1320.
51. Li Y. Effectiveness of oryzanol in the treatment of clozapineinduced salivation reaction. Journal of Nursing Science 2004: 19;72–73.
52. Gross NJ. Ipratropium bromide. N Engl J Med 1988: 319;486– 494.
53. Calderon J, Robin E, Sobota WL. Potential use of ipratropium bromide for the treatment of clozapine induced hypersalivation: a preliminary report. Int Clin Psychopharmacol 2000: 15;49–52.
54. Copp PJ, Lament R, Tennent TG Amitriptyline in clozapine induced sialorrhea. Br J Psychiatry 1991: 159;166.
55. Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology 2006: 185;265–273.
56. Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996: 139 (Suppl.1);43–44.
57. Lu XB, Xue SJ, Yang BZ. A double-blind comparative study of diphenhydramine and placebo in the treatment of sialorrhea caused by clozapine. Sichuan Mental Health 1998: 11;35–37.
58. Yang MZ, Zue SJ,Wen QQ. Effectiveness of diphenhydramine and propantheline in treatment of clozapine-induced hypersalivation: A double blind control study. GuangDong Medicine 1997: 18;731.
59. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003: 1;1279–1281.
60. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003: 18;685–688.
61. Suskind DL, Tilton A. Clinical study of Botulinum-A toxin in the treatment of sialorrhea with children with cerebral palsy. Laryngoscope 2002: 112;73–81.
62. Kahl KG, Hagenah J, Zapf S, Trillenberg P, Klein C, Lencer R. Botulinum toxin as an effective treatment of clozapine induced hypersalivation. Psychopharmacol 2004: 173;229–230.
63. Kang B, Liu YC, Zhang YP, Han Y, Fan LZ, Zhou J. Effect of suo quan pill for reducing clozapine induced salivation. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 1993: 13;347-348.
64. Yuan CM, Zhao XY, Han QY. A control study of the effectiveness of SuoQuanWan and doxepin in the treatment of clozapineinduced hypersalivation. Chinese Journal of Psychiatry 2000: 33;206.
65. Fan QZ, Zhang LY, Duan H, Yu SW, Bu CG, Zhao HQ. Effectiveness of HuangYuanSan in the treatment of clozapine induced hypersalivation: A control study. Sichuan Mental Health 1996: 9; 169–170.
66. Li Y. Effectiveness of oryzanol in the treatment of clozapine induced salivation reaction. Journal of Nursing Science 2004: 19;72–73.
67. Ren QT, Zhao CL, Ma XQ. The therapeutic efficacies of oryzanolum and doxepin on salivation caused by clozapine. Practical Clinical Medicine 2001: 2;31–32.